Appearing as a promising development in the fight against obesity, the drug is attracting considerable interest . This treatment combines effects of two established GLP-1 binding agonists, dulaglutide , and an new glucose-dependent hormonal component. Preliminary study data have indicated impressive body loss in people with a high BMI , perhaps pr